Genmab A/S (NASDAQ:GMAB) to Post FY2024 Earnings of $0.88 Per Share, William Blair Forecasts

Genmab A/S (NASDAQ:GMAB - Free Report) - Stock analysts at William Blair dropped their FY2024 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued on Wednesday, April 17th. William Blair analyst M. Phipps now expects that the company will post earnings per share of $0.88 for the year, down from their previous forecast of $0.89. The consensus estimate for Genmab A/S's current full-year earnings is $1.06 per share. William Blair also issued estimates for Genmab A/S's FY2025 earnings at $1.05 EPS.

A number of other analysts also recently issued reports on GMAB. Morgan Stanley reaffirmed an "underweight" rating on shares of Genmab A/S in a research report on Tuesday, March 26th. BMO Capital Markets raised Genmab A/S from a "market perform" rating to an "outperform" rating and lifted their target price for the company from $46.00 to $48.00 in a research report on Friday, February 23rd. Citigroup downgraded Genmab A/S from a "neutral" rating to a "sell" rating in a research report on Monday, January 22nd. Truist Financial reaffirmed a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Tuesday, March 26th. Finally, HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a report on Thursday, April 4th. Three investment analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $48.50.

Genmab A/S Stock Up 1.3 %

Shares of NASDAQ:GMAB traded up $0.37 during midday trading on Friday, reaching $28.70. The company had a trading volume of 361,029 shares, compared to its average volume of 591,252. The business's 50 day moving average price is $29.38 and its 200 day moving average price is $30.30. The stock has a market cap of $18.98 billion, a PE ratio of 29.90, a P/E/G ratio of 2.05 and a beta of 0.99. Genmab A/S has a 1-year low of $26.32 and a 1-year high of $42.72.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.02. The firm had revenue of $675.29 million for the quarter, compared to the consensus estimate of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%.

Institutional Investors Weigh In On Genmab A/S

A number of institutional investors have recently made changes to their positions in GMAB. JPMorgan Chase & Co. boosted its holdings in shares of Genmab A/S by 42.7% during the first quarter. JPMorgan Chase & Co. now owns 135,116 shares of the company's stock worth $4,889,000 after acquiring an additional 40,444 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Genmab A/S by 4.2% during the first quarter. Bank of New York Mellon Corp now owns 116,847 shares of the company's stock worth $4,227,000 after acquiring an additional 4,665 shares during the period. Private Advisor Group LLC boosted its holdings in shares of Genmab A/S by 24.0% during the first quarter. Private Advisor Group LLC now owns 20,119 shares of the company's stock worth $728,000 after acquiring an additional 3,891 shares during the period. BlackRock Inc. boosted its holdings in shares of Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company's stock worth $198,799,000 after acquiring an additional 86,571 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Genmab A/S by 18.1% during the first quarter. Dimensional Fund Advisors LP now owns 18,243 shares of the company's stock worth $660,000 after acquiring an additional 2,792 shares during the period. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.